

# ASHI Laboratory Manual Edition 4.2

## Table of Contents

Editors .....	i
Preface .....	ii
Table of Contents .....	iii

### VOLUME I: Serological Testing, Cell Mediated Testing and Quality Assurance

#### I. SEROLOGY

##### A. CELL ISOLATION

Guidelines for Specimen Collection, Storage and Transportation .....	I.A.1.1
<i>Louise M. Jacobbi and Paula Blackwell</i>	
Principles of Cell Isolation: Overview of Current Methodologies .....	I.A.2.1
<i>Howard M. Gebel and Robert A. Bray</i>	
Density Gradient Isolation of Peripheral Blood Lymphocytes .....	I.A.3.1
<i>Brenda B. Nisperos</i>	
Augmentation with Monoclonal Antibodies (Lympho-Kwik™) .....	I.A.3.5
Isolation of Lymphocytes from Lymph Nodes and Spleen .....	I.A.4.1
<i>William M. LeFor</i>	
Immunogenetic Isolation of Lymphocyte Subsets Using Monoclonal Antibody-Coated Beads .....	I.A.5.1
<i>Julia A. Hackett and Nancy F. Hensel</i>	
Nylon Wool Separation of T and B Lymphocytes .....	I.A.6.1
<i>Marilena Fotino and Arvind K Menon</i>	
Isolation of T Lymphocytes: A Quick Mini Method for Small Sample Sizes .....	I.A.7.1
<i>Afzal Nikaein</i>	
Rosetting as a Method for Separating Human B Cells and T Cells .....	I.A.8.1
<i>Dod Stewart and Sue Herbert</i>	
Isolation of Monocytes From Peripheral Blood Mononuclear Cells .....	I.A.9.1
<i>Myra Coppage</i>	
Isolation of Endothelial Cells .....	I.A.10.1
<i>Nufatt Leong</i>	
Isolation of Granulocytes .....	I.A.11.1
<i>Prema R. Madyastha</i>	
Assessment of Cell Preparations: A. Viability and B. Purity .....	I.A.12.1
<i>Mary S. Leffel</i>	

## **B. SERUM PREPARATION**

Recalcification of Plasma . . . . . I.B.1.1  
*Herbert A. Perkins, Nancy Sakahara and Zenaida P. Gantan*

Absorption with Lymphocytes . . . . . I.B.2.1  
*Gary A. Teresi and Anne Fuller*

Extraction of Antibodies from Placentas . . . . . I.B.3.1  
*Alan R. Smerglia*

Inactivation of IgM Antibodies: A. DTT Treatment and B. Heat Inactivation . . . . . I.B.4.1  
*Amy B. Hahn*

Depletion of OKT3 From Serum . . . . . I.B.5.1  
*Lori Dombrasuky Osowski and Donna Fitzpatrick*

General Concepts in Preparation of Monoclonal Antibodies . . . . . I.B.6.1  
*Paul J. Martin*

**Removal of interfering Substances from Sera and cells for Screening and Crossmatching:  
Thymoglobulin Removal; Removal of Therapeutic Antibodies with Lymphocyte Cell Lines;  
Pronase treatment of B Lymphocytes . . . . . I.B.7.1**  
*Donna Lucas*

**Strategies to Consider When Confronted With Interfering Therapeutic Substances in  
Patient Samples. . . . . I.B.7.2**  
*Patrick Adams*

## **C. HLA CYTOTOXICITY TESTING**

The Basic Lymphocyte Microcytotoxicity Tests: Standard and AHG Enhancement . . . . . I.C.1.1  
*Katherine A. Hopkins*

Serologic Typing of HLA Antigens by Monoclonal Antibodies . . . . . I.C.2.1  
*Jar-How Lee and Jimmy Loon*

Enhancement of MHC Antigen Expression . . . . . I.C.3.1  
*Patrick W. Adams and Charles G. Orosz*

Granulocyte Antigens and Antibodies. . . . . I.C.4.1  
*Mary E. Clay, Gail Eiber, and Agustin P. Dalmasso*

Fluorochromatic Microgranulocytotoxicity . . . . . I.C.5.1  
*Prema R. Madyastha*

Monocyte Cytotoxicity . . . . . I.C.6.1  
*Peter Stastny*

The Use of Cultured Fetal Cells, Non-Lymphoid Tumor Cells and Fibroblasts for HLA Typing . . . . . I.C.7.1  
*Marilyn Pollack*

Anti-Idiotypic Assay . . . . . I.C.8.1  
*Elaine Reed and Nicole Suciu-Foca*

Lymphocyte Crossmatch: Extended Incubation and Antiglobulin Augmented . . . . . I.C.9.1  
*Patti A. Saiz and Cynthia E. Blanck*

AHG Premixed With Complement: Streamlining for Protocols. . . . . I.C.10.1  
*Laura D. Roberts and Anne Fuller*

Premixing of C' and AHG for Standardization of AHG T Cell Crossmatches . . . . . I.C.11.1  
*Lori Dombrasuky Osowski and Jeffrey McCormack*

T and B Lymphocyte Crossmatches Using Immunomagnetic Beads . . . . . I.C.12.1  
*Smita Vaidya and Todd Cooper*

Interpretation of Cross Match Results . . . . . I.C.13.1  
*Diane J. Pidwell*

## **D. ELISA BASED ASSAYS**

- Crossmatches Using Solubilized Alloantigens . . . . . I.D.1.1  
*Patrice Hennessy, Patrick Adams, and Charles Orosz*
- A Donor-Specific Solid-Phase Immunoassay for the Detection of Anti-MHC Class I and MHC Class II  
Alloantibodies . . . . . I.D.1.2  
*Patrick W. Adams and Charles Orosz*
- HLA Antibody Screening and Identification by ELISA Methodology . . . . . I.D.2.1  
*Lori Dombrausky Osowski, Martin Gutierrez, and Beverly Muth*

## **II. CELLULAR**

### **A. CRYOPRESERVATION**

- Cell Preservation. . . . . II.A.1.1  
*David F. Lorentzen*
- Cryopreservation of Lymphocytes in Bulk . . . . . II.A.2.1  
*D. Michael Strong*
- Cryopreservation of Lymphoblastoid Cell Lines. . . . . II.A.3.1  
*Soldano Ferrone*
- Cryopreservation of Lymphocytes in Trays. . . . . II.A.4.1  
*Donna L. Phelan*

### **B. PREPARATION OF CELL LINES**

- Growth of Lymphoblastoid Cell Lines and Clones . . . . . II.B.1.1  
*Edgar L. Milford and Lisa Ratner*
- Preparation of B-Cell Lines . . . . . II.B.2.1  
*Paul J. Martin*
- T-Cell Cloning . . . . . II.B.3.1  
*Debra K. Newton-Nash and David D. Eckels*
- Propagation of Lymphoid Cells from Biopsies . . . . . II.B.4.1  
*Adriana Zeevi*

### **C. FUNCTIONAL ASSAYS**

- The Mixed Lymphocyte Culture (MLC) Test . . . . . II.C.1.1  
*Eric M. Mickelson, Leigh Ann Guthrie, and John A. Hansen*
- HLA-Dw Typing . . . . . II.C.2.1  
*Nancy Reinsmoen and Eric Mickelson*
- The Primed Lymphocyte Test (PLT) . . . . . II.C.3.1  
*Nancy Reinsmoen*
- In Vitro Measurements of Cell-Mediated Cytotoxicity: Cytotoxic Effector Cells . . . . . II.C.4.1  
*Sandra W. Helman and Malak Y. Kotb*

## **III. QUALITY ASSURANCE**

### **A. THE QUALITY ASSURANCE / IMPROVEMENT PROGRAM**

*Deborah O. Crowe*

- Overview . . . . . III.A.1.1
- Manual . . . . . III.A.1.2
- Forms. . . . . III.A.1.5
- The Quality Assurance Report . . . . . III.A.1.5

Process Improvement . . . . .	III.A.1.6
Benefits of a Quality Assurance Program . . . . .	III.A.1.6

**B. QUALITY ASSURANCE OF INFORMATION / DATA IN THE LABORATORY**

*Lori Dombrowsky-Osowski*

New Test Validation . . . . .	III.B.1.1
Patient Test Management . . . . .	III.B.1.2
Computer Validation . . . . .	III.B.1.4
Laboratory Data Maintenance . . . . .	III.B.1.4

**C. FACILITIES AND ENVIRONMENT**

*Geoffrey A. Land*

Physical Facilities . . . . .	III.C.1.1
Biologic and Chemical Hazards . . . . .	III.C.1.6
Radiation Hazards . . . . .	III.C.1.13

**D. QUALITY CONTROL PROGRAM**

*Anthony L. Roggero and Deborah O. Crowe*

Principle/Purpose . . . . .	III.D.1.1
Proficiency Testing . . . . .	III.D.1.1
Reagent Quality Control . . . . .	III.D.1.1
Complement Quality Control . . . . .	III.D.1.3
Anti-Human Globulin Quality Control. . . . .	III.D.1.3
Primer Quality Control for DNA Typing . . . . .	III.D.1.4
Probe Quality Control for DNA Typing . . . . .	III.D.1.5
Titration of FITC-Anti-Human IgG for Flow Crossmatching . . . . .	III.D.1.6
Equipment Maintenance . . . . .	III.D.1.6
Synthesis of Rare DRB1 Allele Sequences for Quality Control of SSOP . . . . .	III.D.2.1
<i>Debra D. Hiraki, Shalini Krishnaswamy, Carl F. Grumet</i>	
Quality Control for DNA Contamination . . . . .	III.D.3.1
<i>Jeffrey M. McCormack</i>	

**E. REGULATORY AGENCIES**

The Joint Commission on Accreditation of Healthcare Organizations. . . . .	III.E.1.1
<i>Anne Belanger</i>	
ASHI – The HCFA Perspective . . . . .	III.E.2.1
<i>Sandra Pearson and Esther-Marie Carmichael</i>	

**IV. APPENDICES**

**A. CONTRIBUTORS**

**B. STANDARDS**

**C. HLA ALLELES AND EQUIVALENT SEROLOGICAL TYPES**